|
1
|
Xu Z, Yang Q, Chen X, Zheng L, Zhang L, Yu
Y, Chen M, You Q and Sun J: Clinical associations and prognostic
value of site-specific metastases in non-small cell lung cancer: A
population-based study. Oncol Lett. 17:5590–5600. 2019.PubMed/NCBI
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cho BC, Chewaskulyong B, Lee KH,
Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T,
Okamoto I, Zhou C, et al: Osimertinib versus standard of care EGFR
TKI as first-line treatment in patients with EGFRm advanced NSCLC:
FLAURA Asian subset. J Thorac Oncol. 14:99–106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Han X, Luo R, Wang L, Zhang L, Wang T,
Zhao Y, Xiao S, Qiao N, Xu C, Ding L, et al: Potential predictive
value of serum targeted metabolites and concurrently mutated genes
for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients
with EGFR sensitizing mutations. Am J Cancer Res. 10:4266–4286.
2020.PubMed/NCBI
|
|
5
|
Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F
and Ignatius Ou SH: Beyond osimertinib: The development of
third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+
NSCLC. J Thorac Oncol. Dec 15–2020.(Epub ahead of print).
View Article : Google Scholar
|
|
6
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu C and Tan H: The E3 ubiquitin ligase
NEDD4 mediates EGFR-TKI acquired resistance in non-small cell lung
cancer. Int J Clin Exp Med. 12:12013–12019. 2019.
|
|
8
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H
and Xu L: Epigenetic silencing of miR-483-3p promotes acquired
gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting
integrin β3. Oncogene. 37:4300–4312. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang X, Peng Y, Jiang X, Lu X, Duan W,
Zhang S, Dai N, Shan J, Feng Y, Li X, et al: The regulatory role of
APE1 in epithelial-to-mesenchymal transition and in determining
EGFR-TKI responsiveness in non-small-cell lung cancer. Cancer Med.
7:4406–4419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lou W, Chen Y, Zhu KY, Deng H, Wu T and
Wang J: Polyphyllin I overcomes EMT-associated resistance to
erlotinib in lung cancer cells via IL-6/STAT3 pathway inhibition.
Biol Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang B, Yang X, Zhao T, Du H, Wang T,
Zhong S, Yang B and Li H: Upregulation of contactin-1 expression
promotes prostate cancer progression. Oncol Lett. 19:1611–1618.
2020.PubMed/NCBI
|
|
13
|
Chen DH, Yu JW, Wu JG, Wang SL and Jiang
BJ: Significances of contactin-1 expression in human gastric cancer
and knockdown of contactin-1 expression inhibits invasion and
metastasis of MKN45 gastric cancer cells. J Cancer Res Clin Oncol.
141:2109–2120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li GY, Huang M, Pan TT and Jia WD:
Expression and prognostic significance of contactin 1 in human
hepatocellular carcinoma. Onco Targets Ther. 9:387–394. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen N, He S, Geng J, Song ZJ, Han PH, Qin
J, Zhao Z, Song YC, Wang HX and Dang CX: Overexpression of
contactin 1 promotes growth, migration and invasion in Hs578T
breast cancer cells. BMC Cell Biol. 19:52018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi K, Xu D, Yang C, Wang L, Pan W, Zheng
C and Fan L: Contactin 1 as a potential biomarker promotes cell
proliferation and invasion in thyroid cancer. Int J Clin Exp
Pathol. 8:12473–12481. 2015.PubMed/NCBI
|
|
17
|
Yan J, Wong N, Hung C, Chen WX and Tang D:
Contactin-1 reduces E-cadherin expression via activating AKT in
lung cancer. PLoS One. 8:e654632013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu HM, Cao W, Ye D, Ren GX, Wu YN and Guo
W: Contactin 1 (CNTN1) expression associates with regional lymph
node metastasis and is a novel predictor of prognosis in patients
with oral squamous cell carcinoma. Mol Med Rep. 6:265–270.
2012.PubMed/NCBI
|
|
19
|
Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH,
Aziz T, Bismar TA, Wei F, Wong N, De Melo J, et al: Neural cell
adhesion protein CNTN1 promotes the metastatic progression of
prostate cancer. Cancer Res. 76:1603–1614. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coldren CD, Helfrich BA, Witta SE, Sugita
M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW
and Bunn PA Jr: Baseline gene expression predicts sensitivity to
gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res.
4:521–528. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Terai H, Soejima K, Yasuda H, Nakayama S,
Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, et al:
Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism
of acquired resistance to gefitinib in NSCLC. Mol Cancer Res.
11:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gyorffy B, Surowiak P, Budczies J and
Lanczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang R, Sun S, Ji F, Liu C, Lin H, Xie L,
Yang H, Tang W, Zhou Y, Xu J and Li P: CNTN-1 enhances
chemoresistance in human lung adenocarcinoma through induction of
epithelial-mesenchymal transition by targeting the PI3K/Akt
pathway. Cell Physiol Biochem. 43:465–480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song M, Bode AM, Dong Z and Lee MH: AKT as
a therapeutic target for cancer. Cancer Res. 79:1019–1031. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Q, Yu S, Zhao W, Qin S, Chu Q and Wu
K: EGFR-TKIs resistance via EGFR-independent signaling pathways.
Mol Cancer. 17:532018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lei Y, Guo W, Chen B, Chen L, Gong J and
Li W: Tumorreleased lncRNA H19 promotes gefitinib resistance via
packaging into exosomes in nonsmall cell lung cancer. Oncol Rep.
40:3438–3446. 2018.PubMed/NCBI
|
|
28
|
Cho JH, You YM, Yeom YI, Lee DC, Kim BK,
Won M, Cho BC, Kang M, Park S, Yang SJ, et al: RNF25 promotes
gefitinib resistance in EGFR-mutant NSCLC cells by inducing
NF-kB-mediated ERK reactivation. Cell Death Dis. 9:5872018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berglund EO and Ranscht B: Molecular
cloning and in situ localization of the human contactin gene
(CNTN1) on chromosome 12q11-q12. Genomics. 21:571–582. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Haenisch C, Diekmann H, Klinger M,
Gennarini G, Kuwada JY and Stuermer CA: The neuronal growth and
regeneration associated Cntn1 (F3/F11/Contactin) gene is duplicated
in fish: Expression during development and retinal axon
regeneration. Mol Cell Neurosci. 28:361–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mohebiany AN, Harroch S and Bouyain S: New
insights into the roles of the contactin cell adhesion molecules in
neural development. Adv Neurobiol. 8:165–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu P, Chen S, Wu W, Liu B, Shen W, Wang
F, He X and Zhang S: Contactin-1 (CNTN-1) overexpression is
correlated with advanced clinical stage and lymph node metastasis
in oesophageal squamous cell carcinomas. Jap J Clin Oncol.
42:612–618. 2012. View Article : Google Scholar
|
|
33
|
Shigetomi S, Imanishi Y, Shibata K, Sakai
N, Sakamoto K, Fujii R, Habu N, Otsuka K, Sato Y, Watanabe Y, et
al: VEGF-C/Flt-4 axis in tumor cells contributes to the progression
of oral squamous cell carcinoma via upregulating VEGF-C itself and
contactin-1 in an autocrine manner. Am J Cancer Res. 8:2046–2063.
2018.PubMed/NCBI
|
|
34
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH,
Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The
VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
Cancer Cell. 9:209–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Su JL, Yang CY, Shih JY, Wei LH, Hsieh CY,
Jeng YM, Wang MY, Yang PC and Kuo ML: Knockdown of contactin-1
expression suppresses invasion and metastasis of lung
adenocarcinoma. Cancer Res. 66:2553–2561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang R, Yao W, Qian P, Li Y, Jiang C, Ao
Z, Qian G, Wang C, Wu G and Li J: Increased sensitivity of human
lung adenocarcinoma cells to cisplatin associated with
downregulated contactin-1. Biomed Pharmacother. 71:172–184. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC,
Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al:
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per
se is a common mechanism for acquired resistance to EGFR TKI.
Oncogene. 38:455–468. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abkhezr M, Keramati AR, Ostad SN, Davoodi
J and Ghahremani MH: The time course of Akt and ERK activation on
XIAP expression in HEK 293 cell line. Mol Biol Rep. 37:2037–2042.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang G, Long J, Gao Y, Zhang W, Han F, Xu
C, Sun L, Yang SC, Lan J, Hou Z, et al: SETDB1-mediated methylation
of Akt promotes its K63-linked ubiquitination and activation
leading to tumorigenesis. Nat Cell Biol. 21:214–225. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han F, Li CF, Cai Z, Zhang X, Jin G, Zhang
WN, Xu C, Wang CY, Morrow J, Zhang S, et al: The critical role of
AMPK in driving Akt activation under stress, tumorigenesis and drug
resistance. Nat Commun. 9:47282018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Zhang W, Wen L, Yang H, Wen M, Yun
Y, Zhao L, Zhu X, Tian L, Luo E, et al: FOXM1 confers resistance to
gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive
feedback loop. Oncotarget. 7:59245–59259. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang J, Qu Z, Yao H, Sun L, Harata-Lee Y,
Cui J, Aung TN, Liu X, You R, Wang W, et al: An effective drug
sensitizing agent increases gefitinib treatment by down regulating
PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell
lung cancer. Biomed Pharmacother. 118:1091692019. View Article : Google Scholar : PubMed/NCBI
|
